Genotyping of CYP2C9 and VKORC1 in the arabic population of Al-Ahsa, Saudi Arabia

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Alzahrani, Abdullah M ^a   Ragia, Georgia ^b   Hanieh, Hamza ^a   Manolopoulos, Vangelis G ^b  

^a KING FAISAL UNIVERSITY   (Saudi Arabia)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; PROTEIN; UNCLASSIFIED DRUG; VKORC1 PROTEIN; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; ASIAN; CAUCASIAN; DNA POLYMORPHISM; DRUG SENSITIVITY; ETHNICITY; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HUMAN; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SAUDI ARABIA; ETHNIC GROUP; GENETICS; MIDDLE AGED; POPULATION GENETICS;

ADULT; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; SAUDI ARABIA;

EID: 84876557306     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/315980     Document Type: Article

References (41)

1. Manolopoulos V. G., Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clinical Chemistry and Laboratory Medicine 2007 45 7 801 814 2-s2.0-34447269645 10.1515/CCLM.2007.184 (Pubitemid 47041905)
2. Manolopoulos V. G., Ragia G., Tavridou A., Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 2011 12 8 1161 1191
3. Manolopoulos V. G., Ragia G., Tavridou A., Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 2010 11 4 493 496 2-s2.0-77950353192 10.2217/pgs.10.31
4. http://www.cypalleles.ki.se/cyp2c9.htm
5. Xie H. G., Prasad H. C., Kim R. B., Stein C. M., CYP2C9 allelic variants: ethnic distribution and functional significance. Advanced Drug Delivery Reviews 2002 54 10 1257 1270 2-s2.0-0037131892 10.1016/S0169-409X(02)00076-5 (Pubitemid 35284252)
6. Yuan H. Y., Chen J. J., Lee M. T. M., Wung J. C., Chen Y. F., Charng M. J., Lu M. J., Hung C. R., Wei C. Y., Chen C. H., Wu J. Y., Chen Y. T., A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Human Molecular Genetics 2005 14 13 1745 1751 2-s2.0-24944503322 10.1093/hmg/ddi180 (Pubitemid 41430097)
7. Bodin L., Verstuyft C., Tregouet D. A., Robert A., Dubert L., Funck-Brentano C., Jaillon P., Beaune P., Laurent-Puig P., Becquemont L., Loriot M. A., Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005 106 1 135 140 2-s2.0-22044433685 10.1182/blood-2005-01-0341 (Pubitemid 40967184)
8. http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/ ucm123583.pdf
9. Van Schie R. M. F., Wadelius M., Kamali F., Daly A. K., Manolopoulos V. G., De Boer A., Barallon R., Verhoef T. I., Kirchheiner J., Haschke-Becher E., Briz M., Rosendaal F. R., Redekop W. K., Pirmohamed M., Maitland-Van Der Zee A. H., Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009 10 10 1687 1695 2-s2.0-70649084116 10.2217/pgs.09.125
10. French B., Joo J., Geller N. L., Kimmel S. E., Rosenberg Y., Anderson J. L., Gage B. F., Johnson J. A., Ellenberg J. H., Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 2010 11, article 108 2-s2.0-78349294600 10.1186/1745-6215-11-108
11. Do E. J., Lenzini P., Eby C. S., Bass A. R., McMillin G. A., Stevens S. M., Woller S. C., Pendleton R. C., Anderson J. L., Proctor P., Nunley R. M., Davila-Roman V., Gage B. F., Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics Journal 2011 2-s2.0-79956207965 10.1038/tpj.2011.18
12. Schelleman H., Limdi N. A., Kimmel S. E., Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics 2008 9 9 1331 1346 2-s2.0-55449125520 10.2217/14622416.9.9.1331
13. Arvanitidis K., Ragia G., Iordanidou M., Kyriaki S., Xanthi A., Tavridou A., Manolopoulos V. G., Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundamental and Clinical Pharmacology 2007 21 4 419 426 2-s2.0-34447269513 10.1111/j.1472-8206. 2007.00510.x (Pubitemid 47084032)
14. Mirghani R. A., Chowdhary G., Elghazali G., Distribution of the major Cytochrome P450 (CYP) 2C9 genetic variants in a Saudi population. Basic and Clinical Pharmacology and Toxicology 2011 109 2 111 114 2-s2.0-79960264241 10.1111/j.1742-7843.2011.00692.x
15. Saour J. N., Shereen A. W., Saour B. J., Mammo L. A., CYP2C9 polymorphism studies in the Saudi population. Saudi Medical Journal 2011 32 4 347 352 2-s2.0-79953729640
16. Hamdy S. I., Hiratsuka M., Narahara K., El-Enany M., Moursi N., Ahmed M. S. E., Mizugaki M., Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. British Journal of Clinical Pharmacology 2002 53 6 596 603 2-s2.0-0035987174 10.1046/j.1365-2125.2002.01604.x (Pubitemid 34621785)
17. Tanira M. O., Al-Mukhaini M. K., Al-Hinai A. T., Al Balushi K. A., Ahmed I. S., Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. Community Genetics 2007 10 1 32 37 2-s2.0-33845765706 10.1159/000096279 (Pubitemid 46005799)
18. Djaffar-Jureidini I., Chamseddine N., Keleshian S., Naoufal R., Zahed L., Hakime N., Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population. Genetic Testing and Molecular Biomarkers 2011 15 11 827 830
19. Yang L., Ge W., Yu F., Zhu H., Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thrombosis Research 2010 125 4 e159 e166 2-s2.0-77949567067 10.1016/j.thromres.2009.10.017
20. Tavridou A., Petridis I., Vasileiadis M., Association of VKORC1 -1639 G>A polymorphism with carotid intima-media thickness in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2011 94 2 236 241
21. Efrati E., Elkin H., Sprecher E., Krivoy N., Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population. Current Drug Safety 2010 5 3 190 193 2-s2.0-77954669309 10.2174/157488610791698299
22. El-Hazmi M. A. F., Al-Swailem A. R., Warsy A. S., Al-Swailem A. M., Sulaimani R., Al-Meshari A. A., Consanguinity among the Saudi Arabian population. Journal of Medical Genetics 1995 32 8 623 626 2-s2.0-0029115297
23. Weir B., Sunderland M., Disequilibrium. Genetic Data Analysis II 1996 Sinaur Associates 91 139
24. http://www.graphpad.com/quickcalcs/contingency1.cfm
25. Yousef A. M., Bulatova N. R., Newman W., Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Molecular Biology Reports 2012 39 10 9423 9433
26. Sullivan-Klose T. H., Ghanayem B. I., Bell D. A., Zhang Z. Y., Kaminsky L. S., Shenfield G. M., Miners J. O., Birkett D. J., Goldstein J. A., The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996 6 4 341 349 2-s2.0-0029658591 (Pubitemid 26288624)
27. Božina N., Granić P., Lalić Z., Tramišak I., Lovrić M., Stavljenić-Rukavina A., Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croatian Medical Journal 2003 44 4 425 428 2-s2.0-0042888963 (Pubitemid 37098309)
28. Burian M., Grösch S., Tegeder I., Geisslinger G., Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. British Journal of Clinical Pharmacology 2002 54 5 518 521 2-s2.0-0036434235 10.1046/j.1365-2125.2002. 01693.x (Pubitemid 35356878)
29. Scordo M. G., Aklillu E., Yasar U., Dahl M. L., Spina E., Ingelman-Sundberg M., Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. British Journal of Clinical Pharmacology 2001 52 4 447 450 2-s2.0-0034799608 10.1046/j.0306-5251.2001.01460.x (Pubitemid 32939447)
30. Aynacioglu A. S., Brockmöller J., Bauer S., Sachse C., Güzelbey P., Öngen Z., Nacak M., Roots I., Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. British Journal of Clinical Pharmacology 1999 48 3 409 415 2-s2.0-0032819729 10.1046/j.1365-2125.1999.00012.x (Pubitemid 29417726)
31. Allabi A. C., Gala J. L., Desager J. P., Heusterspreute M., Horsmans Y., Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. British Journal of Clinical Pharmacology 2003 56 6 653 657 2-s2.0-0344512432 10.1046/j.1365-2125.2003.01937.x (Pubitemid 37491717)
32. Nasu K., Kubota T., Ishizaki T., Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997 7 5 405 409 2-s2.0-0030868490 10.1097/00008571-199710000-00011 (Pubitemid 27427552)
33. Yoon Y. R., Shon J. H., Kim M. K., Lim Y. C., Lee H. R., Park J. Y., Cha I. J., Shin J. G., Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. British Journal of Clinical Pharmacology 2001 51 3 277 280 2-s2.0-0035040841 10.1046/j.1365-2125.2001.00340.x (Pubitemid 32396418)
34. Zuo J., Xia D., Jia L., Guo T., Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie 2012 67 7 639 644
35. Lee S. S., Kim K. M., Thi-Le H., Yea S. S., Cha I. J., Shin J. G., Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population. Therapeutic Drug Monitoring 2005 27 2 208 210 2-s2.0-16244410164 10.1097/01.ftd.0000153402. 91854.42 (Pubitemid 40463651)
36. Zainuddin Z., Teh L. K., Suhaimi A. W. M., Ismail R., Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism. Journal of Clinical Pharmacy and Therapeutics 2006 31 2 187 191 2-s2.0-33645474219 10.1111/j.1365-2710.2006.00727.x
37. Kudzi W., Dodoo A. N. O., Mills J. J., Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Medical Genetics 2009 10, article 124 2-s2.0-73149102765 10.1186/1471-2350-10-124
38. Zand N., Tajik N., Moghaddam A. S., Milanian I., Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clinical and Experimental Pharmacology and Physiology 2007 34 1-2 102 105 2-s2.0-33846069184 10.1111/j.1440-1681.2007.04538.x
39. Limdi N. A., Goldstein J. A., Blaisdell J. A., Beasley T. M., Rivers C. A., Acton R. T., Influence of CYP2C9 genotype on warfarin dose among African-Americans and European-Americans. Personalized Medicine 2007 4 2 157 169 2-s2.0-34249823331 10.2217/17410541.4.2.157 (Pubitemid 46845895)
40. Wadelius M., Chen L. Y., Lindh J. D., Eriksson N., Ghori M. J. R., Bumpstead S., Holm L., McGinnis R., Rane A., Deloukas P., The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009 113 4 784 792 2-s2.0-59649117935 10.1182/blood-2008-04-149070
41. Ragia G., Petridis I., Tavridou A., Christakidis D., Manolopoulos V. G., Presence of CYP2C9-3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009 10 11 1781 1787 2-s2.0-70649097093 10.2217/pgs.09.96